• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

7.720 +0.180 (+2.39%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verastem, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
December 29, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
December 15, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
November 25, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
November 14, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Proposed Public Offering of Common Stock
November 13, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
November 05, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
November 04, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
October 23, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
October 23, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
October 19, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
August 27, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
August 13, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
August 07, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
July 29, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
July 24, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
July 11, 2025
From Verastem Oncology
Via Business Wire
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MBIO),(NASDAQ:VSTM),(NASDAQ:CRDF),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2025
From Verastem Oncology
Via Business Wire
News headline image
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
From FN Media Group LLC
Via GlobeNewswire
News headline image
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
June 30, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
June 24, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
June 02, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at the Jefferies Global Healthcare Conference
May 28, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
May 22, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
May 13, 2025
From Verastem Oncology
Via Business Wire
News headline image
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
May 08, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at Upcoming Investor Conferences
May 01, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces $75 million Private Placement
April 25, 2025
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
April 23, 2025
From Verastem Oncology
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap